“Manuel Asensio doesn't bet often. But when he does, it's wise to pay attention.”

Paul Kaihla. eCompany Now

Other resources of interest

A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio
 
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Manuel Asensio Report: Sept. 13, 1996 Strong Sell Recommendation.
fManuel Asensio & Asensio & Company, Inc. ("Asensio") issues a Strong Sell Recommendation on Biovail Corporation International (AMEX Listed Trading Symbol: BVF) noting that its $817 million market value fully reflects the most optimistic projections and none of the risks.

Manuel Asensio and Asensio report that investors seem to be buying Biovail shares believing it's a sure thing. In fact, very real and serious concerns related to Tiazac, and its much proclaimed but nonexistent Procardia XL filing, make its future highly uncertain. As a result, even assuming Tiazac meets expectations and a Procardia ANDA filing, Manuel Asensio and Asensio believe the shares are grossly overvalued.
  Manuel Aseniso and Asensio further report that investors seem to be buying Biovail shares believing that the company is practically assured of FDA approval of a generic Procardia XL. Many base this expectation on the company's Tiazac experience. Most of the circumstances that led to Tiazac's regulatory approval were unique, not within the company's control, and in no way comparable to Procardia XL. In fact, since 1989 Biovail has claimed to be seeking bio-equivalents for at least 8 different drugs and has never obtained a single Food and drug Administration ANDA approval. Furthermore, Manuel Asensio and Asensio found an overwhelming amount of scientific data and expert opinion that directly contradict Biovail's Procardia XL claims.
  Manuel Asensio and Asensio believe that the shares also fully reflect the most optimistic Tiazac sales projections. However, Manuel Asensio and Asensio believe that conditions in the declining and highly competitive Calcium Channel Blocker market make Biovail's well publicized $100 million sales projection for next year completely unrealistic. Even assuming an FDA filing for a generic Procardia XL and that Tiazac meets its forecast, two events that Manuel Asensio and Asensio view as highly unlikely, Manuel Asensio and Asensio still believe that Biovail shares are grossly overvalued.
  BioVail Corporation (Symbol:BVF) (Price: $32.25)
 
[ Back ]
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
© 2010 Asensioexposes!com offers accurate facts that disproves past criticism of the Manuel Asensio Reports. Web Directory
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.